Biologic treatment of pediatric rheumatic diseases: are we spoilt for choice?

Approximately 15 years ago the first biological treatment for juvenile idiopathic arthritis (JIA) was introduced. Since the introduction of the TNF receptor fusion protein etanercept in 1998, now more than seven biologics are now registered, or under study for JIA. [...]when pharmaceuticals submit a...

Full description

Saved in:
Bibliographic Details
Published inImmunotherapy Vol. 6; no. 1; pp. 1 - 3
Main Authors van Royen-Kerkhof, Annet, Vastert, Bas SJ, Swart, Joost F, Wulffraat, Nico M
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.01.2014
Subjects
Online AccessGet full text

Cover

Loading…